July 2, 2008
Clarient Introduces New Colorectal Cancer Test
Clarient has launched its new offering, Kras, which has been validated as a laboratory-developed test to be used as a predictive molecular biomarker for patients with colorectal cancer.
In colorectal cancers, EGF-receptors transmit a series of signals through a complex path of intracellular proteins. These signals ultimately instruct the cancer cell to undergo a transcription process leading to cancer progression. Anti-EGF-receptor therapies such as panitumumab and cetuximab work by blocking the activation of EGF-receptor. By blocking activation of the receptor, these drugs are successful in inhibiting downstream events that lead to malignant signaling.
Ron Andrews, CEO of Clarient, said: "Identifying the Kras mutation can help individual patients and their physicians understand the best way to manage their disease, assisting them in selecting the most appropriate therapy."